Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , June 7, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards on June 5, 2019,
Toggle Summary Audentes Therapeutics Announces Changes to Senior Management Team
- Edward R. Conner, M.D. appointed as Senior Vice President and Chief Medical Officer - Fulvio Mavilio, Ph.D. promoted to Senior Vice President of Translational Science - Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM, Senior Vice President and Chief Medical Officer and John Gray, Ph.D.
Toggle Summary Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
SAN FRANCISCO , May 8, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the Bank of
Toggle Summary Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM - On track to submit updated ASPIRO data package with optimal dose selection to FDA in the second quarter of 2019 and to provide update on the license application submission plans for AT132 in
Toggle Summary Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
- New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 - Significant and sustained improvements in neuromuscular function in both dose cohorts, with corresponding achievement of clinically meaningful motor
Toggle Summary Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
SAN FRANCISCO , April 30, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , April 26, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards
Toggle Summary Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
- Facility further establishes the company's leadership in AAV manufacturing and enables the rapid advance of neuromuscular programs from preclinical development to commercialization SAN FRANCISCO , April 23, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a leading AAV-based
Toggle Summary Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
- Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2 - Presentation to be featured in the plenary session "Presidential Symposium & Presentation of the Top
Toggle Summary Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy
- Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) - Exclusive license agreement with the Research Institute at Nationwide